恒瑞医药：帕立骨化醇软胶囊获得药品注册批准

Core Viewpoint - Heng Rui Medicine (600276.SH) announced that its subsidiary Chengdu Shengdi Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration (NMPA) for the market launch of Paricalcitol soft capsules, aimed at treating secondary hyperparathyroidism (SHPT) in adults with chronic kidney disease (CKD) stages 3-4 [1] Company Summary - The approved indication for Paricalcitol soft capsules is for the prevention and treatment of secondary hyperparathyroidism in adults suffering from chronic kidney disease stages 3-4 [1]